Location: Denver
Synced from ClinicalTrials.gov · July 28, 2026
Clinical studies recruiting near Denver
Studies with at least one listed site matching this
location on the public registry. Each page explains the study in plain
language, with locations and study-team contacts.
Clinicians: generate a
printable list for your patient →
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Phase 1/Phase 2 · Sarah Cannon Research Institute at HealthOne · Eikon Therapeutics · NCT06907043Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
Phase 2 · National Jewish Health · Johns Hopkins University · NCT07059091Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplant
Phase 2 · Presbyterian / St. Luke's Medical Center · New York Blood Center · NCT01656603Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
Phase N/A · Jaeb Center for Health Research · NCT06837181Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Remo
Phase 2/Phase 3 · Kaiser Permanente-Franklin · National Cancer Institute (NCI) · NCT05987241Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
NA · University of Colorado · Uromedica · NCT04248283First In Human Study of CX-2051 in Advanced Solid Tumors
Phase 1 · Sarah Cannon Research Institute at HealthONE · CytomX Therapeutics · NCT06265688A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phase 1/Phase 2 · Sarah Cannon Research Institute at HealthONE · Phanes Therapeutics · NCT05652686JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
Phase 2 · Denver Health Hospital and Authority · PPD Development, LP · NCT06701656RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Th
Phase N/A · Boston Scientific Corporation · NCT01719055Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Phase N/A · The Women's Imaging Center · ECOG-ACRIN Cancer Research Group · NCT06002828A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Phase 1/Phase 2 · Sarah Cannon Research Institute at HCA HealthONE Presbyteria · Bayer · NCT06914128Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
Phase 2 · Colorado Blood Cancer Institute (CBCI) · Massachusetts General Hospital · NCT06561347Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
NA · Denver Health Hospital Authority · Johns Hopkins University · NCT06080698A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
Phase 2 · BioRestorative Therapies · NCT04042844AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Phase 1/Phase 2 · Research Site · AstraZeneca · NCT05850234A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With
Phase 3 · Colorado Blood Cancer Institute · Janssen Research & Development, LLC · NCT07258511A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric
Phase 3 · Children's Hospital Colorado. · Hoffmann-La Roche · NCT05199688A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metasta
Phase 2 · Ohio State University Telemedicine · Sameek Roychowdhury · NCT06906562Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Phase 3 · Vertex Pharmaceuticals Incorporated · NCT06628908Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Phase 2 · Cancer Center of Colorado at Sloan's Lake · SWOG Cancer Research Network · NCT04205968A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharma
Phase 1 · Research Site · AstraZeneca · NCT07073547A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
Phase 2 · Colorado Kidney Care Nephrology · Novartis Pharmaceuticals · NCT07146906A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light
Phase 1 · Colorado Blood Cancer Institute · Janssen Research & Development, LLC · NCT05652335VISN 19 MIRECC Research Database
Phase N/A · VA Eastern Colorado Health Care System · VA Eastern Colorado Health Care System · NCT01334476Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Phase 2 · Cancer Center of Colorado at Sloan's Lake · SWOG Cancer Research Network · NCT05040360Study of HLD-0915 in Patients With Metastatic Prostate Cancer
Phase 1/Phase 2 · Sarah Cannon Research Institute at HealthONE · Janssen Research & Development, LLC · NCT06800313To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
Phase 2 · Expedition Therapeutics, Inc · NCT07684820JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
Phase 2 · Denver Health Hospital and Authority · PPD Development, LP · NCT06701682Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combina
Phase 2/Phase 3 · Local Institution - 007-872-E · Mirati Therapeutics Inc. · NCT04613596
Look up another city
Look up another condition